News Pfizer will have to cut price of AML drug Mylotarg after NIC... NICE blocks access to 65% of patients on cost grounds
News NICE asks EUSA pharma to drop price of neuroblastoma drug NICE calls for price cut before possible CDF funding
News Report warns of UK's rare disease 'postcode lottery' There is still a ‘postcode lottery’ for patients getting access to vital rare disease treatments in the UK, according to a new report.
Market Access Row over CF drug funding as NHS rejects Vertex offer Vertex 'astonished and dismayed' by NHS rejection
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
